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 In the United States, gonorrhea and chlamydia account for the majority of sexually 
transmitted infections (STI) and are estimated to cost almost $1 billion in direct medical 
expenses annually (Centers for Disease Control and Prevention, 2018). Oftentimes, gonorrhea 
and chlamydia are thought to infect only the urogenital tract; however, these infections can be 
harbored at extragenital sites as well, including the rectum and oropharynx. Routine extragenital 
screening recommendations exist for populations deemed higher risk, such as men who have sex 
with men (MSM). However, screening does not appear to be completed consistently despite 
evidence in the literature supporting its use. In many instances, STI screening may only include 
screening for urogenital infections in this population; therefore, MSM may be at higher risk of 
undiagnosed extragenital gonorrhea and chlamydia infection.  
 Primary care is an area of medicine focused on the prevention of many diseases and is a 
suitable place to perform routine extragenital screenings; yet, there is a significant mismatch 
between current screening rates and screening recommendations throughout the United States. 
The clinical site where this project was implemented did not regularly offer screening for 
extragenital gonorrhea and chlamydia. Prior to this project, many of the participating clinicians 
reported a lack of knowledge regarding who should be offered screening, how to order screening 
tests, and how to complete testing. Additional barriers such as clinician comfort, patient comfort, 
and lack of patient education were also identified. These barriers were collectively addressed 
through the implementation of a risk assessment tool that would allow for better screening rates 




 Gonorrhea and chlamydia are the two most frequently diagnosed bacterial sexually 
transmitted infections (STI) worldwide (World Health Organization, 2015). MSM are 
disproportionately affected by STIs (Earnest et al., 2020; Johnson-Jones et al., 2019), and 
extragenital gonorrhea and chlamydia infections are common within this population. In addition, 
certain sexual behaviors in this population, such as condomless receptive anal intercourse and 
oral sex, can increase the likelihood of infection at extragenital locations (Kumar et al., 2020). 
The majority of gonorrhea and chlamydia cases in MSM are thought to be asymptomatic 
(Passaro et al., 2018; Yang et al., 2018). This includes infections at any anatomic site (urogenital, 
rectal, and oropharyngeal) but particularly at extragenital locations.  
 Research conducted through 2015 reported that prevalence ranges for rectal gonorrhea 
were 0.2-24% (median 5.9%) and for rectal chlamydia were 2.1-23% (median 8.9%). For 
oropharyngeal gonorrhea prevalence ranges were 0.5-16.5% (median 4.6%) and for 
oropharyngeal chlamydia were 0-3.6% (median 1.7%) (Chan et al., 2016). Additionally, high 
percentages of gonorrhea and chlamydia cases would have been missed if only urogenital 
screenings were completed (Anschuetz et al., 2020; Abara et al., 2016; Chan et al., 2016). In one 
study, 80% of MSM participants who tested positive for chlamydia and 77% who tested positive 
for gonorrhea were only positive at extragenital sites (Danby et al., 2016). 
 According to the Centers for Disease Control and Prevention (CDC) (2015), guidelines 
for STI screening in sexually active MSM include at least annual screening at all exposed 
anatomic sites (Johnson Jones et al., 2019). In addition, more frequent screening (every 3-6 
months) is recommended for MSM at elevated risk for STIs and for those MSM taking pre-
exposure prophylaxis medication (PrEP) (CDC, 2017b). Despite these recommendations, only 
3 
 
42% of American MSM reported any STI screening test within the past 12 months, and only 
16% reported any extragenital screening (de Voux, Bernstein, Kirkcaldy, Zlotorzynska, & 
Sanchez, 2019). Lack of adherence to extragenital screening recommendations is likely to 
increase the overall disease burden of gonorrhea and chlamydia due to a higher risk of 
transmission that exists when asymptomatic extragenital infections go undiagnosed (Lutz, 2015). 
Furthermore, infections at extragenital sites can increase susceptibility to other more serious 
diseases such as human immunodeficiency virus (HIV) (Barbee et al., 2017; Katz, Dombrowski, 
Bell, Kerani, & Golden, 2016). 
Project Methods 
 This project on screening men who have sex with men (MSM) for extragenital gonorrhea 
and chlamydia was inspired by a question of inquiry to improve the care, screening rates, and 
early identification of sexually transmitted infections (STI) in MSM. The project aim was to 
improve screening rates for extragenital gonorrhea and chlamydia in MSM within a primary care 
setting by using a risk assessment tool to address multiple barriers to screening. Institutional 
Review Board (IRB) approval was sought through OSF St. Joseph Medical Center and Southern 
Illinois University Edwardsville to evaluate current knowledge of providers and screening 
measures for this at-risk patient population. The research project was deemed non-human subject 
research by both IRBs. 
 The project was conducted at a large Internal Medicine office in Bloomington, Illinois. 
Eleven practicing clinicians (3 physicians, 2 physician assistants, and 6 nurse practitioners) 
participated in the project.  Before project implementation, the clinicians completed an initial 
evaluation by filling out the “Clinician Knowledge of Extragenital STI Screening” questionnaire. 
Clinicians were then provided an educational session that included important background 
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information on extragenital STI infections and how to use the risk assessment tool properly. The 
risk assessment tool was adapted from the “Sexual Risk Assessment and Risk Factors for 
Sexually Transmitted Diseases” form currently used by the California Department of Public 
Health (California Department of Public Health, 2015). The adapted version, titled “STI Risk 
Screening Questionnaire for Men Who Have Sex with Men,” was given to eligible patients 
identified by medical office assistants during the rooming process of all preventative and STI 
screening office visits. 
Evaluation 
 The main instrument used for evaluation was a 10-item questionnaire titled “Clinician 
Knowledge of Extragenital STI Screening.” This questionnaire was created to examine clinician 
knowledge on extragenital screening for gonorrhea in MSM and risk factors for transmission, 
comfort level with assessing a patient’s risk status, and how frequently the clinician offered 
extragenital screening to their patients. This questionnaire was given to the clinicians prior to 
implementation of the risk assessment tool, “STI Risk Screening Questionnaire for Men Who 
Have Sex with Men,” and seven weeks after implementation of the tool. In the follow-up 
questionnaire one additional question was added to better assess the effectiveness of the 
screening tool as a way to improve extragenital screening rates. The additional item read, “After 
implementation of the risk assessment screening tool, how likely are you to regularly offer 
screening for extragenital gonorrhea and chlamydia when appropriate?” 
 Prior to project implementation, 73% of clinicians reported no knowledge or only slight 
knowledge of extragenital STI screening recommendations for MSM, and 82% of clinicians 
reported no knowledge or only slight knowledge of subsequent health risks after extragenital 
STI. Regarding comfort, 91% of clinicians reported only slight or moderate comfort taking 
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detailed sexual history with MSM patients, and 82% of clinicians reported only slight or 
moderate comfort explaining the importance of extragenital STI screening to those patients. 
Finally, 73% of clinicians reported rarely offering or never offering extragenital screening as part 
of preventative exam, and only 18% sometimes offered extragenital screening as part of that 
exam. When patients sought STI screening 64% of clinicians reported rarely offering or never 
offering extragenital screening, and only 18% reported sometimes offering it. When a patient 
reported possible STI exposure, 55% of clinicians reported rarely offering or never offering 
extragenital screening and only 18% reported sometimes offering extragenital screening. 
 In the follow-up questionnaire, 82% of clinicians now reported being moderately or very 
knowledgeable regarding extragenital STI screening recommendations for MSM. Similarly, 82% 
of clinicians now reported being moderately or very knowledgeable regarding subsequent health 
risks after extragenital STI, while the remaining 18% reported being extremely knowledgeable. 
Regarding comfort, 82% of clinicians now reported being moderately or very comfortable taking 
a detailed sexual history with MSM patients and also with explaining the importance of 
extragenital STI screening to those patients. In both instances, the remaining 18% reported 
feeling extremely comfortable. 
 Finally, now only 45% of clinicians reported rarely offering or never offering extragenital 
screening as part of preventative exam, while 55% reported sometimes or frequently offering 
extragenital screening as part of that exam. When patients sought STI screening 64% of 
clinicians now reported sometimes or frequently offering extragenital screening, and one 
clinician reported always offering it. The same ratings were reported by clinicians when a patient 
reported possible STI exposure. 
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 Perhaps the most important reported finding from the follow-up questionnaire had to do 
with the additional item that was added. Due to the narrow population focus and limited number 
of times the risk assessment tool could be used in practice during the seven weeks of the study, 
this item served as a way to gather clinicians’ overall feelings of usefulness and effectiveness for 
the tool. With use of the risk assessment tool in practice, 45% of clinicians reported being 
moderately or very likely to offer extragenital screening for gonorrhea and chlamydia when 
appropriate; an additional 45% of clinicians reported being extremely likely. 
 After implementing the educational session and the risk assessment tool, clinicians had 
an improved knowledge base with extragenital STIs and were reportedly more comfortable 
discussing and offering to screen when appropriate. More importantly, clinicians reported being 
more likely to offer extragenital screenings with use of the risk assessment tool in place. The risk 
assessment tool seemed to have addressed numerous barriers that were previously preventing 
extragenital STI screening from taking place, including lack of clinician knowledge, lack of 
clinician comfort, and ease of identifying and offering screenings to eligible patients.  This 
process and risk assessment tool allows eligible patients to be identified efficiently and risk-
stratified so screening can be offered when appropriate. The clinician now has an opportunity to 
more easily and comfortably engage in a conversation regarding sexual health with their patients. 
 Several limitations exist in this project. Firstly, this project was limited by the number of 
clinicians participating. Since the project was implemented in a single primary care office, the 
number of participants was limited to 11. While results were promising among this sample, the 
project conclusions may not be generalizable to a larger group of clinicians. Secondly, the results 
of the questionnaire, particularly the initial questionnaire, may have been limited by the phrasing 
of the questions. A few clinicians may have incorrectly interpreted the questions on the survey as 
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being about general STI screening and not extragenital screening alone. This may have slightly 
misrepresented just how few extragenital screenings were being completed prior to 
implementation of the risk assessment tool. Finally, as previously mentioned, the project is 
limited in its narrow population focus. Since the project focused only on MSM attending 
preventative or STI screening visits, which collectively represented a very small number of 
patients, the risk assessment tool had limited ability to be used and assessed for its effectiveness. 
Impact on Practice 
 The implementation of a risk assessment tool has allowed clinicians to better identify 
MSM at high risk of extragenital gonorrhea and chlamydia. As a result, clinicians are better able 
to offer screening to their patients when appropriate and feel more comfortable discussing the 
risks and benefits of routine screening. On a larger scale, performing more frequent extragenital 
gonorrhea and chlamydia screening in MSM will help reduce the transmission burden, especially 
in asymptomatic carriers. Additionally, MSM patients will now be better educated on the 
importance of extragenital STI screening and may be more inclined to pass that information onto 
their partners or other close friends. Finally, providing more comprehensive STI screening 
through this process may reduce susceptibility to HIV and create opportunities to more 
consistently discuss and offer HIV prevention options such as PrEP. 
 Continued use of the risk assessment tool should allow for long-term success and 
sustainability with this practice change. It is important that MOAs continue to ask the basic 
sexual health history questions so, the risk assessment tool will consistently be given to 
appropriate patients. Over time, clinicians may gain confidence and comfort in discussing a 
patient’s sexual health history, assessing extragenital infection risk, and offering screening 
without the use of the risk assessment tool. This project can be considered successful and 
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sustainable even if the risk assessment tool is not used long-term. Whether the risk assessment 
tool continues to be used if patients are consistently risk-stratified and offered extragenital STI 
screening when appropriate, this project should be considered a success. 
Conclusions 
 Implementation of a risk assessment tool was shown to increase the likelihood that 
clinicians would routinely offer extragenital screening for gonorrhea and chlamydia in MSM. 
Tools such as the one used in this project may be beneficial in addressing many of the barriers 
which currently prevent screening rates from meeting CDC recommendations for screening. 
With increased screening rates for extragenital STIs in MSM, population health will be improved 
through reduced transmission rates of gonorrhea and chlamydia as well as the possibility of 
decreasing susceptibility to HIV infection. In the future, this project can be expanded beyond the 
MSM population to include others who might be susceptible to extragenital infection, including 
any individual engaging in receptive anal intercourse or receptive oral sex regardless of their 
gender. Furthermore, other screenings with poor compliance, such as rectal HPV, which is 
known to contribute to the development of rectal cancer, could be improved by using this project 
as a model. 
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